One of the characteristics we have seen in our analysis of COVID-19 contracts is heterogeneity. The Bayh-Dole was enacted in 1980 to provide for uniform provisions on funding agreements regarding the ownership of inventions and the public’s rights. But for… Continue Reading
KEI is an accredited non-state actor at the World Health Organization (WHO). This was the oral statement we delivered during the resumed session of the WHA 73 in November 2020. Our statement focused on agenda item 11.9 – Global strategy… Continue Reading
On November 7, 2020, the Department of Health and Human Services (HHS) posted another COVID-19 vaccine contract: the $1 billion agreement between Janssen Pharmaceutical (a component of Johnson & Johnson (“J&J”)) and the U.S. government (through an intermediary called Advanced… Continue Reading
The resumed session of the 73rd session of the World Health Assembly (WHA) meets this week from 9 November 2020 to 14 November 2020. As the Republic and Canton of Geneva has imposed a lockdown since 2 November 2020, the… Continue Reading
DRAGONS’ LAIR Thursday, 12 November 2020 – 15:00 CET, 14:00 UTC On Thursday, 12 November 2020 from 14h00 UTC to 15h30 UTC, Knowledge Ecology International (KEI) invites you to Dragons’ Lair – a pitch for WIPO’s work program for the… Continue Reading
On November 5, 2020, Regeneron Pharmaceuticals published a redacted version of the contract awarding the company $450 million taxpayers’ dollars for the large-scale manufacture of Regeneron’s investigational COVID-19 antibody treatment. The contract uses Other Transactions Authority to weaken the U.S.… Continue Reading
A contract between Regeneron and Advanced Technology International (ATI) involving $450 million in taxpayer funding uses the “Other Transactions Authority” or OTA, to avoid Bayh-Dole safeguards on patent rights. ATI is entering into purchase agreements on behalf of the Department… Continue Reading
Moderna has attached three COVID-19 related contracts as exhibits to its SEC 10-Q form for the quarterly period ending in October 2020. The first is the contract between the Department of Health and Human Services (HHS) and Moderna for the… Continue Reading
Lilly recently requested an emergency use authorization for LY-CoV555, an antibody treatment candidate against COVID-19. Like other COVID-19 candidates, the discovery of LY-CoV555 was heavily supported by the U.S. government. The government of Canada has also awarded millions to manufacture… Continue Reading
Regeneron Pharmaceuticals failed to disclose U.S. government funding in a patent that claims antibodies against COVID-19. The obligation to acknowledge U.S. government funding in patents is required under an existing contract between Regeneron and the Biomedical Advanced Research and Development… Continue Reading